Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2276

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2276
---
 the price you paid for our securities. In such circumstances,
the trading price of our securities may not recover and may experience a further decline.

The
market price of our securities may decline as a result for a number of other reasons including:

    ●
    if
    the effect of the Business Combination on our business and prospects is not consistent with the expectations of securities or industry
    analysts;

    ●
    if
    we do not achieve the perceived benefits of the Business Combination as rapidly or to the extent anticipated by securities or industry
    analysts;

    ●
    actual
    or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar
    to us;

    ●
    changes
    in the market’s expectations about our results of operations;

    ●
    success
    of competitors;

    ●
    changes
    in financial estimates and recommendations by securities analysts concerning us or the biopharmaceutical industry in general;

    ●
    operating
    and share price performance of other companies that investors deem comparable to us;

    ●
    our
    ability to market new and enhanced products and technologies on a timely basis;

129

    ●
    changes
    in laws and regulations affecting our business;

    ●
    our
    ability to meet compliance requirements;

    ●
    commencement
    of, or involvement in, litigation involving us;

    ●
    changes
    in our capital structure, such as future issuances of securities or the incurrence of additional debt;

    ●
    the
    volume of our securities available for public sale; or

    ●
    any
    major change in our board of directors or management.

Certain
existing stockholders purchased our securities at a price below the current trading price of such securities, and may experience a positive
rate of return based on the current trading price.

Certain
of our securityholders acquired shares of our common stock or warrants at prices below the current trading price of our common stock,
and may experience a positive rate of return based on the current trading price. Such securityholders may be incentivized to sell their
securities at prices below the prevailing trading price of such securities because the prices at which they acquired their shares may
be lower than prevailing market prices and/or the prices at which public investors purchased our securities in the open market, and therefore
such shareholders may generate positive rates of return on their investment that would not be available to public shareholders that acquired
their securities at higher